DBV TECHNOLOGIE/S (DBVT) Cut to Strong Sell at BidaskClub

BidaskClub downgraded shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a sell rating to a strong sell rating in a report published on Friday.

Several other equities analysts have also recently weighed in on DBVT. Leerink Swann reaffirmed an outperform rating on shares of DBV TECHNOLOGIE/S in a research note on Thursday, December 20th. Zacks Investment Research raised DBV TECHNOLOGIE/S from a sell rating to a hold rating in a research note on Wednesday, December 5th. Stifel Nicolaus cut DBV TECHNOLOGIE/S from a buy rating to a hold rating and set a $11.00 target price on the stock. in a research note on Thursday, December 20th. Jefferies Financial Group cut DBV TECHNOLOGIE/S from a buy rating to a hold rating and set a $5.25 target price on the stock. in a research note on Thursday, December 20th. Finally, HC Wainwright reduced their price target on DBV TECHNOLOGIE/S from $50.00 to $25.00 and set a buy rating for the company in a report on Thursday, December 20th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company’s stock. DBV TECHNOLOGIE/S presently has a consensus rating of Hold and a consensus target price of $21.93.

NASDAQ:DBVT opened at $6.26 on Friday. DBV TECHNOLOGIE/S has a fifty-two week low of $3.60 and a fifty-two week high of $26.89. The stock has a market cap of $372.08 million, a price-to-earnings ratio of -1.86 and a beta of 2.02.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of DBV TECHNOLOGIE/S by 4.7% during the second quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock valued at $5,970,000 after purchasing an additional 14,032 shares during the period. FMR LLC grew its position in DBV TECHNOLOGIE/S by 1.4% in the third quarter. FMR LLC now owns 1,325,676 shares of the company’s stock valued at $29,775,000 after acquiring an additional 18,744 shares during the period. Perceptive Advisors LLC grew its position in DBV TECHNOLOGIE/S by 42.8% in the third quarter. Perceptive Advisors LLC now owns 3,009,998 shares of the company’s stock valued at $67,604,000 after acquiring an additional 901,800 shares during the period. Exane Asset Management grew its position in DBV TECHNOLOGIE/S by 30.0% in the third quarter. Exane Asset Management now owns 65,000 shares of the company’s stock valued at $1,460,000 after acquiring an additional 15,000 shares during the period. Finally, First Midwest Bank Trust Division grew its position in DBV TECHNOLOGIE/S by 19.3% in the third quarter. First Midwest Bank Trust Division now owns 163,358 shares of the company’s stock valued at $3,669,000 after acquiring an additional 26,372 shares during the period. Institutional investors and hedge funds own 44.99% of the company’s stock.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Recommended Story: Certificate of Deposit (CD) For Risk Adverse Investors?

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply